Feasibility of Imaging Esophageal Cancer with Labeled Somatostatin Analogue
Table 1
Tumor type, size, and location, CT result, and 99mTc-depreotide uptake in 21 esophageal cancer patients.
Diagnosis
Tumor size in mm
Location
CT
99mTc-depreotide
1
Sqcc
5
Middle
Neg.
Neg.
2
Ac
17 × 45
Distal
Pos.
Pos.
3
Sqcc
55 × 40
proximal
Pos.
Pos.
4
Ac in B.
65 × 55 × 13
Distal
Pos.
Pos.
5
Ac
90 × 75 × 25
Distal
Pos.
Pos.
6
Imc and B.
12 × 9
Distal
Neg.
Neg.
7
Sqcc
30 × 10
Middle
Pos
Pos
8
Ac
20 × 90
Middle
Pos.
Pos.
9
Ac
60 × 25 × 9
Distal
Pos.
Pos.
10
Sqcc
50 × 45
Distal
Pos.
Pos.
11
Small cell cancer
110 × 24
Middle
Pos.
Pos.
12
Ac in B
60 × 65
Distal
Pos.
Pos.
13
Ac
25 × 15
Distal
Neg.
Pos.
14
Ac in B
20 × 25
Distal
Pos.
Pos.
15
Sqcc
60 × 10
proximal
Pos.
Pos.
16
Sqcc
15 × 55
Distal
Pos.
Pos.
17
Ac
15 × 50
Distal
Pos.
Pos.
18
Ac
15 × 15
Distal
Neg.
Neg.
19
Ac in B
20 × 25
Distal
Neg.
Neg.
20
Sqcc
14 × 5
Middle
Neg.
Pos.
21
Sqcc
23 × 38 × 12
Distal
Pos.
Neg.
Ac: adenocarcinoma; Sqcc: squamous cell carcinoma; B: Barrett's esophagus; Imc: intramucosal cancer. 99mTc-depreotide uptake classified as negative or positive based on visual assessment. CT pos.: tumor is visible on the CT images; CT neg.: tumor is not visible on the CT images.
